Similar articles

• Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register.

  Modell B, Khan M, Darlison M. Modell B, et al. Lancet. 2000 Jun 10;355(9220):2051-2. doi: 10.1016/S0140-6736(00)02357-6. Lancet. 2000. PMID: 10885361
• Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients.

  Hatzipantelis ES, Karasmanis K, Perifanis V, Vlachaki E, Tziomalos K, Economou M. Hatzipantelis ES, et al. Hemoglobin. 2014;38(2):111-4. doi: 10.3109/03630269.2013.867407. Epub 2013 Dec 18. Hemoglobin. 2014. PMID: 24351163
• Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients.

  Olivieri NF, Matsui D, Liu PP, Blendis L, Cameron R, McClelland RA, Templeton DM, Koren G. Olivieri NF, et al. Bone Marrow Transplant. 1993;12 Suppl 1:9-11. Bone Marrow Transplant. 1993. PMID: 8374574 Clinical Trial.
• Optimizing iron chelation strategies in beta-thalassaemia major.

  Porter JB. Porter JB. Blood Rev. 2009 Dec;23 Suppl 1:S3-7. doi: 10.1016/S0268-960X(09)70003-7. Blood Rev. 2009. PMID: 20116637 Review.
• Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.

  Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Delea TE, et al. Transfusion. 2007 Oct;47(10):1919-29. doi: 10.1111/j.1537-2995.2007.01416.x. Transfusion. 2007. PMID: 17880620 Review.